Surgeons and investigators from Cedars-Sinai Orthopaedics bring their leading-edge expertise in treatment and the latest clinical research to the annual meeting of the American Academy of Orthopaedic Surgeons (AAOS) in San Francisco February 12-16.
The Department of Radiation Oncology at Cedars-Sinai Cancer has earned accreditation from the American Society for Radiation Oncology (ASTRO) Accreditation Program for Excellence.
Imagine a world in which the digital watch on your wrist tracks not only your step count, but also your blood sugar, heart rate, blood pressure and respiration.
Cedars-Sinai and BlackDoctor.org will host a virtual community conversation to help inspire Black doctors considering a career in medicine, research and healthcare.
Cedars-Sinai will host 10 Dutch health technology startups in Los Angeles to share best practices on bringing innovative ideas and products to the U.S. market.
Physicians in the Smidt Heart Institute at Cedars-Sinai have achieved two significant firsts: completing the institute’s 100th minimally invasive tricuspid valve replacement and performing the first-ever implantation of a new bioprosthetic tricuspid valve following its approval by the U.S. Food and Drug Administration (FDA).
The Continuing Medical Education program at Cedars-Sinai has earned Joint Accreditation with Commendation, enhancing continuing education opportunities for healthcare professionals and signifying that Cedars-Sinai upholds the highest standards in providing relevant, effective, practice-based education.
Cedars-Sinai Cancer investigators have discovered a protein expressed on multiple myeloma cancer cells that drives disease growth and development. The new study found that blocking part of the protein’s unique signaling pathway stops myeloma growth in culture and in laboratory mice.
Investigators from Cedars-Sinai; the University of California, San Francisco (UCSF); Harvard University; and the Weizmann Institute of Science in Israel conducted a study to determine where individual nutrients are absorbed in the small intestine. For the first time, they identified the molecular markers that define five distinct intestinal regions.
High-risk pregnancy specialists from Cedars-Sinai will share their research findings at the Society for Maternal-Fetal Medicine 2024 Pregnancy Meeting, Feb.10-14, in National Harbor, Maryland.
Cedars-Sinai clinicians and artificial intelligence experts have developed a new application that takes advantage of the unique capabilities of Apple Vision Pro to support patients’ mental health needs.
Physician-scientists from the Comprehensive Stroke Center at Cedars-Sinai will be attending the International Stroke Conference Feb. 6-9 in Phoenix and are available to discuss the latest stroke news and research.
The Cedars-Sinai Comprehensive Transplant Center and Smidt Heart Institute together completed 652 solid organ transplants in 2023, far outpacing Cedars-Sinai’s internal record set just one year ago, when surgeons completed 583 transplants.
Nicolas Musi, MD, studies a spectrum of age-related disorders that can impact a healthy lifespan.
Surgeons and investigators from the Cedars-Sinai Orthopaedic Department will lead sessions featuring a range of orthopedic research at the 70th Annual Meeting of the Orthopaedic Research Society (ORS), Feb. 2-6, 2024, in Long Beach, Calif.
Investigators in the Department of Computational Biomedicine at Cedars-Sinai wanted to find out which factors influenced susceptibility to COVID-19 infection and disease severity the most. Was it genetics? Or was it home environment, meaning the germs circulating throughout your everyday life?
Chemotherapy can be toxic to heart cells. To help protect the hearts of cancer patients, Cedars-Sinai investigators have created a three-dimensional “heart-on-a-chip” to evaluate drug safety.
Thomas M. Priselac, whose leadership over the last 30 years as Cedars-Sinai’s president and CEO significantly expanded the scope and quality of its clinical, educational, research and community benefit programs, has announced his plans to retire.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai for January 2024.
Like the rest of the country, Los Angeles County has experienced a dramatic upswing in overdoses from fentanyl, an opiate that is 100 times stronger than heroin.
Cardiologists and cardiac and vascular surgeons from the Smidt Heart Institute at Cedars-Sinai are available for interviews throughout February to discuss heart-related topics, including the latest advances in research and patient care.
Cedars-Sinai and Space Tango are planning their third launch of pilot-scale systems for the automated in-space production of stem cells to the International Space Station.
Interventions to address the risks older people can face taking multiple medications need significant improvement, according to a study by Cedars-Sinai investigators.
Cardiothoracic surgeons and investigators from the Smidt Heart Institute at Cedars-Sinai will lead sessions featuring a range of heart procedures at the 60th Annual Meeting of The Society of Thoracic Surgeons (STS), Jan. 27-29, 2024, in San Antonio, Texas.
Investigators from the Smidt Heart Institute at Cedars-Sinai and colleagues found that women with fatty liver disease related to alcohol consumption have almost twice the risk of dying within a certain time period than men with the same condition.
You may not know Carol Barr, but in the future, she could save your life. Barr’s death at 39 from sudden cardiac arrest was caused by mitral valve prolapse—a heart valve defect that can affect the heart’s ability to pump blood. It can, in some cases, lead to death.
A team of experts from Cedars-Sinai International will participate in Arab Health, Jan. 29-Feb. 1, in Dubai, United Arab Emirates, underscoring Cedars-Sinai’s commitment to growing its worldwide presence by supporting innovative, advanced collaborative medical care for millions of patients around the globe.
The View Hospital in affiliation with Cedars-Sinai is proud to announce that it will host the inaugural "Innovations in Orthopedics Symposium" on Jan. 27 at the Equestrian Club in Doha, Qatar.
Cedars-Sinai Cancer investigators have used a unique precision medicine and artificial intelligence (AI) tool called the Molecular Twin Precision Oncology Platform to identify biomarkers that outperform the standard test for predicting pancreatic cancer survival.
A roundup of 2023 medical discoveries and innovations at Cedars-Sinai Cancer.
Heart rhythm expert Sumeet Chugh, MD, associate director of the Smidt Heart Institute at Cedars-Sinai, is the recipient of this year’s American College of Cardiology (ACC) Distinguished Scientist Award-Clinical Domain.
New research by investigators from the Department of Psychiatry and Behavioral Neurosciences at Cedars-Sinai shows that behavioral activation therapy is as effective as antidepressant medications in treating symptoms of depression in patients with heart failure.
Yvette Bordelon, MD, PhD, who specializes in some of the most difficult-to-treat movement disorders, has joined the Movement Disorders Program in the Department of Neurology at Cedars-Sinai. She will work on clinical trials and treat patients with Parkinson’s disease, Huntington’s disease and other movement disorders, which currently have no cure.
One of the Smidt Heart Institute’s leading experts in artificial intelligence, David Ouyang, MD, has been named a deputy editor of NEJM AI—a newly established, peer-reviewed journal from the publishers of the highly respected, New England Journal of Medicine.
Cedars-Sinai investigators are using electronic health records to identify hospitalized patients likely to have dementia. The method they developed, detailed in a study published in the peer-reviewed Journal of the American Geriatrics Society, is designed to help medical staff tailor care to best serve these patients.
Women who received standard recommended immunizations during their pregnancy were more likely to accept the COVID-19 vaccine, according to new research from Cedars-Sinai. Investigators also identified disparities in vaccination linked to race and insurance status.
The choices that Bruce Gold faced last December to resolve debilitating symptoms from a severely enlarged prostate were to keep using a catheter or have an invasive surgery with unreliable results and a high risk of complications and lingering side effects.
Cedars-Sinai Cancer investigators have analyzed the cells within triple-negative breast cancer tumors before and after radiation therapy with immunotherapy, identifying three patient groups with different responses to the treatment.
As the new year kicks into full swing, so has a trio of respiratory viruses, creating a so-called tripledemic.
A new research study from the Smidt Heart Institute at Cedars-Sinai aimed to understand the possible connection between COVID-19 vaccination and a difficult-to-diagnose heart condition called postural orthostatic tachycardia syndrome, or POTS.
A roundup of the latest medical discoveries and faculty news at Cedars-Sinai for December 2023.
Wars abroad. Struggles at home, including record-setting inflation and political polarization. Although the holiday season can trigger a range of emotions, this year may feel especially challenging.
The Smidt Heart Institute at Cedars-Sinai has opened an Aortic Surveillance Clinic for the evaluation and long-term monitoring of patients with enlarged aortas, or aortic aneurysms, for whom surgery may not be necessary.
New research from the Smidt Heart Institute at Cedars-Sinai found that women who developed signs of elevated blood pressure during pregnancy were more likely to have residual evidence of abnormal heart structure and function up to a decade after the pregnancy.
Cedars-Sinai Cancer investigators have discovered a new way to predict whether a cancer of the immune system will recur in patients treated with a bone marrow transplant.
Cedars-Sinai Cancer is part of an unconventional consortium dedicated to fighting cancer through the integration of diverse scientific disciplines.
In the summer of 2022, an overwhelmed Jon Anderson was nervously preparing for a big moment—having robotic coronary artery bypass surgery. Just over a year later, in the fall of 2023, Anderson was staring down another major life event.
An artificial intelligence (AI) tool developed by investigators at the Smidt Heart Institute at Cedars-Sinai and colleagues at two other institutions accurately predicted how patients would fare after surgeries and procedures.
New research from Cedars-Sinai’s Comprehensive Transplant Center found that a monoclonal antibody treatment reduced the risk of COVID-19 in a large group of solid organ transplant patients who were administered the drug as a preventive measure against the disease.
The Smidt Heart Institute at Cedars-Sinai has expanded its popular Virtual Second Opinion Program to women living with or at risk of developing heart disease, the nation’s leading cause of death in women.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
